close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0012 UNCHANGED
Last Price Updated: 3:34 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
Via ACCESSWIRE
News headline image
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
Via ACCESSWIRE
News headline image
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
Via ACCESSWIRE
News headline image
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Via ACCESSWIRE
News headline image
Lexaria Awarded New Patents
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Via ACCESSWIRE
News headline image
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
Via ACCESSWIRE
News headline image
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Lexaria's Submits Investigational New Drug Application
Via ACCESSWIRE
News headline image
Lexaria Releases Annual Letter from the CEO
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's Investigational New Drug Application Filing Update
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Granted Two New Patents in Canada
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today